For the quarter ending 2025-09-30, KLRS had -$46,039K decrease in cash & cash equivalents over the period. -$11,516K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,894 | -21,546 |
| Depreciation expense | 3 | - |
| Stock-based compensation expense | 638 | 965 |
| Change in fair value of derivative liabilities (including 1,165 and 860 for a related party) | 0 | 1,229 |
| Change in fair value of tranche liability (including 331 and 0 for a related party) | 0 | 365 |
| Non-cash interest expense (including 1,384 and 1,392 for a related party) | 0 | 1,443 |
| Non-cash operating lease expense | -12 | - |
| Net amortization of premiums and accretion of discounts on investments | 83 | - |
| Loss on extinguishment and on issuance of convertible promissory notes (including 169 and 2,134 for a related party) | 0 | -186 |
| Prepaid expense and other current assets | -2,041 | 588 |
| Other non-current assets | 89 | 281 |
| Accrued compensation | - | -1,073 |
| Accounts payable | -3,202 | 2,240 |
| Accrued expenses and other current liabilities (including 20 and 36 for a related party) | 151 | 268 |
| Operating lease liabilities | 17 | - |
| Net cash used in operating activities | -11,333 | -19,980 |
| Purchase of short-term investments | 34,523 | - |
| Purchase of property and equipment | 183 | - |
| Net cash used in investing activities | -34,706 | - |
| Proceeds from the issuance of convertible promissory notes (including 3,402 and 9,993 from a related party), net of issuance costs | 0 | 7,500 |
| Cash acquired in connection with the merger | 0 | 102,113 |
| Payment of deferred transaction costs and issuance costs | 0 | 2,346 |
| Net cash provided by financing activities | 0 | 107,267 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -46,039 | 87,287 |
| Cash and cash equivalents at beginning of period | 1,639 | - |
| Cash and cash equivalents at end of period | 42,887 | - |
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)